15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Dyne Therapeutics Inc, 9 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $16.00 to $50.00 (about 3.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $35.20 sits 37% above the current $25.66. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.76 next quarter toward $-2.93 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy19%
Buy873%
Hold218%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Dyne Therapeutics Inc.
As of Jul, 9 of 11 firms rate DYN a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DYN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.76
Range $-0.90 – $-0.60 · 14 analysts · +0% YoY
Next period, 14 analysts expect Dyne Therapeutics Inc to earn $-0.76 a share (range $-0.90 – $-0.60), versus $-0.76 a year earlier. Full-year consensus is $-3.06, growing to $-2.93 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 14 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $51.8M next year.
Top analysts covering Dyne Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DYN.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$38.00+48.1% to target
Overall win rate
41%
+ Follow
#2
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$45.00+75.4% to target
Overall win rate
29%
+ Follow
#3
Andreas Argyrides
Oppenheimer
Buy
$40.00+55.9% to target
Coverage
—
+ Follow
#4
AG
Ananda Ghosh
HC Wainwright & Co.
Buy
$50.00+94.9% to target
Coverage
—
+ Follow
#5
GC
Gavin Clark-Gartner
Evercore ISI Group
Buy
$33.00+28.6% to target
Coverage
—
+ Follow
DYN stock forecast FAQ
What is DYN's average 12-month price target?+
The 10 analysts with a live target average $35.20 for Dyne Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $16.00 low.
Is DYN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 9 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DYN?+
The Street-high target is $50.00 (HC Wainwright & Co.), and the Street-low is $16.00 (JP Morgan). The average of all 10 active targets is $35.20.
How many Wall Street analysts cover DYN?+
11 analysts have an active rating on Dyne Therapeutics Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering DYN?+
Among analysts who currently cover DYN, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $38.00 target.
What is Dyne Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.76 per share (range $-0.90 – $-0.60) across 14 analysts. Full-year EPS is projected at $-3.06, rising to $-2.93 the following year.
How much revenue is Dyne Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $51.8M next year.
Have analysts been upgrading or downgrading DYN lately?+
As of Jul, 9 of 11 firms rate DYN a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DYN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
